Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 5, 2020
Daily News
August 5, 2020
- LTL Pharma to Take Over Sanofi’s Dellegra in Japan
August 5, 2020
- NIBIOHN, US Biotech to Develop COVID-19 Replicon RNA Vaccine; Japan PII Eyed Next Summer
August 5, 2020
- Astellas’ Q1 Sales Falter 8% on Deal Terminations, COVID-19
August 5, 2020
- Celltrion Poised to Roll Out 20 Biosimilars in Japan over Next 10 Years
August 5, 2020
- Povidone-Iodine Gargle Meds Fly Off Pharmacy Shelves after Osaka COVID-19 Data
August 5, 2020
- First Patient Enrolled in Clinical Trial to Test 3 Drugs for COVID-19: AbbVie, Amgen, Takeda
August 5, 2020
- Mitsubishi Tanabe’s Sales Drop 6.5% in Q1, 5 Billion Yen Loss on Price Cuts
August 5, 2020
- PeptiDream, RayzeBio Tie Up on Peptide-Radiotherapeutics
August 5, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…